![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Inovio’s COVID-19 Vaccine Poised for Phase 3 Trial, but FDA Partial Hold Remains
Inovio’s COVID-19 Vaccine Poised for Phase 3 Trial, but FDA Partial Hold Remains
![Inovio_Logo.png](https://www.fdanews.com/ext/resources/test/Drug-Images4/Inovio_Logo.png?t=1607401365&width=430)
Inovio Pharmaceuticals has announced that its COVID-19 vaccine candidate, INO-4800, was shown to be safe and well-tolerated in a phase 2 clinical trial.
The company’s plan for a phase 3 trial is delayed due to a partial clinical hold by the FDA because of questions about the company’s proprietary intradermal DNA delivery device used to administer the vaccine.
Inovio said the results from the 400-person phase 2 study will help answer the agency’s questions and that the phase 3 trial will advance once the hold is lifted.
Upcoming Events
-
18Jul
-
21Oct